Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale

被引:40
作者
Ponomarenko, NA
Durova, OM
Vorobiev, II
Belogurov, AA
Telegin, GB
Suchkov, SV
Misikov, VK
Morse, HC
Gabibov, AG
机构
[1] RAS, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[2] Vladimirsky Moscow Reg Clin Inst, Moscow, Russia
[3] Moscow MV Lomonosov State Univ, Dept Chem, Moscow 119899, Russia
[4] RAS, Pushchino Branch Shemyakin, Pushchino 142290, Russia
[5] RAS, Ovchinnikov Inst Bioorgan Chem, Pushchino 142290, Russia
[6] Natl Inst Allergy & Infect Dis, Lab Immunopathol, NIH, Rockville, MD 20852 USA
基金
美国国家卫生研究院; 俄罗斯基础研究基金会;
关键词
autoantibody to myclin basic protein; multiple sclerosis; catalytic antibodies; EDSS;
D O I
10.1016/j.imlet.2005.10.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoantibodies toward myelin basic protein (MBP) evidently emerge in sera and cerebrospinal fluid of the patients with multiple sclerosis (MS), as well as in a MS rodent model, i.e., experimental autoimmune encephalomyelitis (EAE). The studies of the last two decades have unveiled somewhat controversial data on the diagnostic applicability of anti-MBP autoantibodies as a disease' marker. Here, we present the results of new functional analysis of the anti-MBP autoantibodies isolated from MS (in patients) and EAE (in mice) sera, based on their proteolytic activity against the targeted autoantigen. The activity was shown to be the intrinsic property of the IgG molecule. No activity was found in the sera-derived antibody fraction of healthy donors and control mice. Sera of 24 patients with clinically proven MS at different stages of the disease, and 20 healthy controls were screened for the anti-MBP antibody-mediated proteolytic activity. The activity correlated with the scores on the MS expanded disability status scale (EDSS) (r(2) =0.85, P < 0.001). Thus, the anti-MBP autoantibody-mediated proteolysis may be regarded as an additional marker of the disease progression. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 22 条
[1]  
[Anonymous], 1988, Antibodies: A Laboratory Manual
[2]   Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event [J].
Berger, T ;
Rubner, P ;
Schautzer, F ;
Egg, R ;
Ulmer, H ;
Mayringer, I ;
Dilitz, E ;
Deisenhammer, F ;
Reindl, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (02) :139-145
[3]   A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response. [J].
Bischof, F ;
Bins, A ;
Dürr, M ;
Zevering, Y ;
Melms, A ;
Kruisbeek, AM .
JOURNAL OF IMMUNOLOGY, 2004, 173 (01) :600-606
[4]   A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosis [J].
Chamczuk, AJ ;
Ursell, M ;
O'Connor, P ;
Jackowski, G ;
Moscarello, MA .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 262 (1-2) :21-27
[5]   DETECTION OF BRAIN-REACTIVE AUTOANTIBODIES IN THE SERA OF AUTOIMMUNE MICE USING ELISA [J].
CRIMANDO, J ;
HOFFMAN, SA .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 149 (01) :87-95
[6]   High levels of catalytic antibodies correlate with favorable outcome in sepsis [J].
Lacroix-Desmazes, S ;
Bayry, J ;
Kaveri, SV ;
Hayon-Sonsino, D ;
Thorenoor, N ;
Charpentier, J ;
Luyt, CE ;
Mira, JP ;
Nagaraja, V ;
Kazatchkine, MD ;
Dhainaut, JFO ;
Mallet, VO .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (11) :4109-4113
[7]   The prevalence of proteolytic antibodies against factor VIII in hemophilia A. [J].
Lacroix-Desmazes, S ;
Bayry, J ;
Misra, N ;
Horn, MP ;
Villard, S ;
Pashov, A ;
Stieltjes, N ;
d'Oiron, R ;
Saint-Remy, J ;
Hoebeke, J ;
Kazatchkine, MD ;
Kaveri, SV .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :662-667
[8]   Catalytic activity of antibodies against factor VIII in patients with hemophilia A [J].
Lacroix-Desmazes, S ;
Moreau, A ;
Sooryanarayana ;
Bonnemain, C ;
Stieltjes, N ;
Pashov, A ;
Sultan, Y ;
Hoebeke, J ;
Kazatchkine, MD ;
Kaveri, SV .
NATURE MEDICINE, 1999, 5 (09) :1044-1047
[9]  
LI L, 1995, J IMMUNOL, V154, P3328
[10]  
MILLS JP, 1996, HADRONIC J, V19, P1